dc.contributor.author |
Hay, Michael |
en |
dc.contributor.author |
Hicks, Kevin |
en |
dc.contributor.author |
Wang, Jingli |
en |
dc.date.accessioned |
2018-10-23T19:27:31Z |
en |
dc.date.issued |
2014-01 |
en |
dc.identifier.uri |
http://hdl.handle.net/2292/43340 |
en |
dc.description.abstract |
Hypoxia is an important component of the tumor microenvironment and has been the target of drug discovery efforts for almost half a century. These efforts have evolved from offsetting the impact of hypoxia on radiotherapy with oxygen-mimetic radiosensitizers to using hypoxia as a means to selectively target tumors. The more recent description of hypoxia-inducible factors and their role in the hypoxia response network has revealed a host of new drug targets to selectively target tumors. We are developing hypoxia-directed drugs in each of the following areas: novel radiosensitizers for hypofractionated radiotherapy, a second-generation benzotriazine di-N-oxide hypoxia-activated prodrug, and a hypoxia-inducible factor-1-dependent cytotoxin that targets glucose transport. These projects are discussed in the context of hypoxia-directed drug discovery. |
en |
dc.format.medium |
Print |
en |
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. |
en |
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
en |
dc.subject |
Animals |
en |
dc.subject |
Humans |
en |
dc.subject |
Neoplasms |
en |
dc.subject |
Antineoplastic Agents |
en |
dc.subject |
Radiation-Sensitizing Agents |
en |
dc.subject |
Cell Hypoxia |
en |
dc.subject |
DNA Repair |
en |
dc.subject |
Hypoxia-Inducible Factor 1 |
en |
dc.subject |
Drug Discovery |
en |
dc.subject |
Molecular Targeted Therapy |
en |
dc.subject |
Tumor Microenvironment |
en |
dc.title |
Hypoxia-directed drug strategies to target the tumor microenvironment. |
en |
dc.type |
Book Item |
en |
dc.identifier.doi |
10.1007/978-1-4614-5915-6_6 |
en |
pubs.begin-page |
111 |
en |
pubs.volume |
772 |
en |
dc.rights.holder |
Copyright: The author |
en |
dc.identifier.pmid |
24272357 |
en |
pubs.end-page |
145 |
en |
pubs.publication-status |
Published |
en |
dc.rights.accessrights |
http://purl.org/eprint/accessRights/RestrictedAccess |
en |
pubs.elements-id |
421464 |
en |
pubs.org-id |
Medical and Health Sciences |
en |
pubs.org-id |
Medical Sciences |
en |
pubs.org-id |
Auckland Cancer Research |
en |
pubs.org-id |
Science |
en |
pubs.org-id |
Science Research |
en |
pubs.org-id |
Maurice Wilkins Centre (2010-2014) |
en |
pubs.record-created-at-source-date |
2013-11-25 |
en |
pubs.dimensions-id |
24272357 |
en |